Nasdaq:CNSP
CNS Pharmaceuticals, Inc.
A loss-making biopharmaceutical firm investing heavily in R&D with no current revenue but substantial cash financing inflows.
Key Metrics
Investment Thesis
Bull Case
Investors might consider this stock if they believe the clinical pipeline has high success potential and can generate significant future revenue once approved. The company's ability to raise capital through share issuances suggests strong investor confidence in its long-term asset value despite current losses. A single blockbuster drug could transform the balance sheet given the current low total liabilities of $2.5M.
Bear Case
The stock carries extreme risk as the company has zero revenue and a massive accumulated deficit of $84.4M with no visible path to profitability in the near term. Negative cash flow from operations of $17.1M indicates that current business models are not self-sustaining without continuous dilution or external funding. The lack of income over the last three years suggests a high probability of bankruptcy if financing dries up.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing novel therapeutic solutions primarily targeting rare diseases and specific oncology indications. The company operates in the competitive small-cap biotech sector, currently navigating a phase of high capital expenditure to advance its clinical pipeline while managing significant cash burn rates.
Analysis
Management Discussion
Management has prioritized pipeline advancement over revenue generation, evidenced by $9.3M allocated to R&D and $5.6M in G&A expenses while maintaining a loss of $14.9M in 2024. Despite the negative operating profit, the company successfully secured $23.0M from financing activities to offset cash burn, though it continues to report a net change in cash of only $5.9M against a large deficit.
Industry Overview
The biopharmaceutical industry is characterized by high failure rates in drug development, long regulatory timelines, and the necessity for substantial upfront investment before any commercial returns are realized. Small-cap companies like CNS Pharmaceuticals often rely on venture capital or public markets to fund their research until they achieve market exclusivity. Success depends entirely on the ability to navigate clinical trials and secure favorable regulatory outcomes in a crowded therapeutic landscape.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $15.3M | $18.9M | $14.9M |
| Operating Income | $-15.3M | $-18.9M | $-14.9M |
| R&D | $9.3M | $14.1M | $9.3M |
| G&A | $6.0M | $4.8M | $5.6M |
| Stock-Based Comp | $1.2M | $1.0M | $839.0K |
| Depreciation | $11.8K | $4.1K | $3.3K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Expense | $7.0K | $13.8K | — |
| Pre-Tax Income | $-15.3M | $-18.9M | $-14.9M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-15.3M | $-18.9M | $-14.9M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-15.3M | $-18.9M | $-14.9M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-15.3M | $-18.9M | $-14.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $12.6M | $1.6M | $8.7M |
| Cash & Equivalents | $10.1M | $548.7K | $6.5M |
| Prepaid Expenses | $2.5M | $839.6K | $1.3M |
| Other Current Assets | $0 | $202.9K | $903.2K |
| Long-Term Assets | $488.5K | $109.7K | $42.4K |
| PP&E (Net) | $5.7K | $4.9K | $6.0K |
| Other LT Assets | $482.8K | $104.8K | $36.4K |
| Total Assets | $13.1M | $1.7M | $8.7M |
| Current Liabilities | $4.9M | $6.1M | $2.5M |
| Accounts Payable | $3.7M | — | — |
| Other Current Liab | $410.0K | — | — |
| Long-Term Liabilities | $0 | $0 | $0 |
| Total Liabilities | $4.9M | $6.1M | $2.5M |
| Shareholders' Equity | $8.1M | $-4.4M | $6.2M |
| Paid-In Capital | $58.8M | $65.1M | $90.6M |
| Retained Earnings | $-50.7M | $-69.6M | $-84.4M |
| Total L&E | $13.1M | $1.7M | $8.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-15.3M | $-18.9M | $-14.9M |
| Non-Cash Adjustments | $3.3M | $5.8M | $1.3M |
| Working Capital Changes | $1.4M | $-1.1M | $-3.6M |
| Cash from Operations | $-10.6M | $-14.1M | $-17.1M |
| Capital Expenditures | $4.4K | $3.9K | $4.2K |
| Cash from Investing | $-4.4K | $-3.9K | $-4.2K |
| Cash from Financing | $15.6M | $4.6M | $23.0M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $5.1M | $-9.5M | $5.9M |
| Beginning Cash | $5.0M | $10.1M | $548.7K |
| Ending Cash | $10.1M | $548.7K | $6.5M |
Frequently Asked Questions
How does CNS Pharmaceuticals, Inc. make money?
The company's financials indicate a pre-revenue stage operation where costs are driven entirely by Research and Development ($9.3M), General and Administrative expenses ($5.6M), and significant Capital Expenditures ($4.2M) rather than traditional product sales segments.
What are the main risks for CNSP?
1. Complete dependence on external equity financing as the company has generated no revenue ($0) over the last five years. 2. Severe profitability challenges with a net loss of $14.9M in 2024 and a retained earnings deficit of $84.4M. 3. High cash burn rate exacerbated by negative operating cash flows of $17.1M and significant non-operating cash outflows.
What is CNSP's competitive advantage?
1. Deep pipeline potential in high-value rare disease or oncology therapeutic areas with limited competition at the early stage. 2. Strong access to capital demonstrated by $23.0M in financing cash flows and a paid-in capital base of $90.6M. 3. Minimal debt burden with zero long-term liabilities and manageable current liabilities relative to working capital.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.